Eris Lifesciences Limited (ERIS.BO)
Eris Lifesciences Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Ahmedabad, GU, IN. The stock last traded at $1358.60, down 1.57% on the session, giving a market capitalisation of $188.34B. Its beta of -0.04 implies it has historically moved less than the broad market.
Eris Lifesciences Ltd., along with its affiliated companies, operates in India, specializing in the production, promotion, and supply of proprietary pharmaceutical drugs aimed at treating chronic and semi-chronic health conditions. The company's extensive product portfolio encompasses a wide array of branded formulations across numerous therapeutic categories, including treatments for diabetes, infections, cardiovascular ailments, dermatological issues, digestive disorders, blood-related conditions, hormonal imbalances, central nervous system disorders, neuropsychiatric conditions, ear complaints, pain relief, respiratory illnesses, oral health, cosmetic applications, women's health, and essential vitamins/minerals/nutrients. Furthermore, Eris provides vital patient support services, such as blood pressure measurement, portable electrocardiogram monitoring, continuous glucose tracking, sleep evaluations, and prenatal care programs. Its pharmaceutical offerings reach consumers via a robust distribution network comprising wholesale drug distributors, stockists, and retail pharmacies. Established in 2007, Eris Lifesciences Limited maintains its headquarters in Ahmedabad, India.
Eris Lifesciences Limited is most often compared with the following Healthcare names: